S&P Futures
4,078.75 -11.25 (-0.28%) Dow Futures
34,004.00 -152.00 (-0.45%) Nasdaq Futures
12,139.00 -13.00 (-0.11%) Russell 2000 Futures
1,936.50 -2.90 (-0.15%) Crude Oil
79.13 +0.26 (+0.33%) Gold
1,945.40 +0.10 (+0.01%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.1801 |
| Open | 0.1811 |
| Bid | 0.1814 x 800 |
| Ask | 0.1875 x 1200 |
| Day's Range | 0.1800 - 0.1900 |
| 52 Week Range | 0.1180 - 1.2000 |
| Volume | |
| Avg. Volume | 4,103,088 |
| Market Cap | 19.962M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7180 |
| Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.33 |
- GlobeNewswire
Athenex Announces MHRA Decision on Oral Paclitaxel
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical efficacy or safety concerns were expressed BUFFALO, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, a
- American City Business Journals
Athenex to close Clarence plant, lay off 92 employees
Athenex Pharma Solutions will close its plant on Main Street in Clarence, according to a notice posted to the state’s Department of Labor website on Dec. 23. The global biopharmaceutical company plans to close the site March 17, with 92 employees being laid off. Athenex representatives could not be reached, but according to the state Department of Labor, the reason for the closing was “economic.”
- GlobeNewswire
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroupBUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that collaborators at the Quantum Leap Healthcare Collaborative reported today that the Company’s oral paclitaxel plus encequ
